Nanopath
Cambridge, United States · Biotechnology, Health Care
Nanopath is a molecular diagnostics company disrupting traditional testing methodologies. We aim to improve the health of women by providing granular and clinically actionable information within a single office visit.
Key facts
- Headquarters
- Cambridge, United States
- Employees
- 25
- Industries
- Biotechnology, Health Care
- Status
- Private
- Website
- nanopath.com
- Company page
Recent activity at Nanopath
- : Nanopath announces the close of a $25 million Series B financing to advance molecular testing for women's health, co-led by Norwest and SV Health Investors.
- : Nanopath Appoints Edward Evantash as Chief Medical Officer and Matthew Black as Chief Scientific Officer
- : Nanopath
- : Nanopath Inc. received $4m in federal funding to support the development of its point-of-care diagnostic platform for women’s health.
- : Nanopath Secures $10 Million In Series A Funding To Develop And Commercialize Point-Of-Care Diagnostics For Women's Health
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Nanopath funding history
| Date | Round | Amount |
|---|---|---|
| Nov 2026 | Series B | $25.0M |
| Jan 2025 | Venture | $5.3M |
| May 2024 | Seed | $4.0M |
| Aug 2022 | Series A | $10.0M |
Leadership
- Amogha Tadimety, Co-Founder & CEO
- Matt Cote, Vice President of Engineering
- Matthew Black, Chief Scientific Officer
- Edward Evantash, Chief Medical Officer
- Alison Burklund, Chief Executive Officer
Verified email and direct lines for Nanopath’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Nanopath files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Nanopath in the news
- FDA grants breakthrough device designation to diagnostic test for cUTIs - Urology Times (Nov 18, 2025)
- Vaginitis Test Startup Nanopath Lands Labcorp In $25 Million Series B - Forbes (Nov 16, 2026)
- Nanopath Announces $25 Million Series B Financing to Advance Molecular Testing for Women’s Health - Fitt Insider (Nov 11, 2026)
- Nanopath Granted FDA Breakthrough Device Designation for Its Molecular Diagnostic Platform for Urinary Tract Infections - PR Newswire (Nov 18, 2025)
- Cambridge-based Nanopath raises funds to revolutionize women's health through diagnostics - The Business Journals (Aug 11, 2022)
- Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation - PR Newswire (May 21, 2024)
- Nanopath Secures $10 Million in Series A Funding to Develop and Commercialize Point-of-Care Diagnostics for Women's Health - PR Newswire (Aug 09, 2022)
Companies similar to Nanopath
- Navigator Medicines · Biotechnology, Health Care
- Tenpoint Therapeutics · Biotechnology, Health Care
- Wrango · Biotechnology, Health Care
- Paradigm Biopharmaceuticals · Biotechnology, Health Care
- Oath Surgical · Biotechnology, Health Care
About Nanopath: questions and answers
What does Nanopath do?
Nanopath is a molecular diagnostics company disrupting traditional testing methodologies. We aim to improve the health of women by providing granular and clinically actionable information within a single office visit.
Where is Nanopath headquartered?
Nanopath is headquartered in Cambridge, United States.
How many employees does Nanopath have?
Nanopath has about 25 employees.
Has Nanopath raised funding?
Yes. Fundz has recorded 4 funding events for Nanopath. The most recent, Series B of $25.0M, was in Nov 2026.
Who leads Nanopath?
Amogha Tadimety is a Co-Founder & CEO at Nanopath.
What is the latest news on Nanopath?
On Nov 10, 2026, Nanopath announces the close of a $25 million Series B financing to advance molecular testing for women's health, co-led by Norwest and SV Health Investors.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy